RxDoctor Payments Data

Vijay Choudhry, MD

Internal Medicine · Philadelphia, PANPI 1639283062

Payments from drug & device makers

$890in general payments, 2019–2025

Across 44 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$171
  • Exact Sciences$116
  • GSK$111
  • Lilly USA, LLC$109
  • Johnson & Johnson$67
  • AbbVie$59
  • plus $257 from 8 others

What the payments were for

  • Food & beverage$890100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$890 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$18,728
Medicare patients
54
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$66,740
EliquisApixaban50$35,132
OzempicSemaglutide29$35,053
TrulicityDulaglutide34$32,086
JanuviaSitagliptin Phosphate16$21,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,720
LinzessLinaclotide16$11,215
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$8,577
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,655
Albuterol Sulfate HfaAlbuterol Sulfate173$4,682
Atorvastatin Calcium264$3,391
SymbicortBudesonide/Formoterol Fumarate14$3,023
Novolog FlexpenInsulin Aspart14$2,030
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$1,951
Rosuvastatin Calcium71$1,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$44$66,74059 claims
PfizerEliquis$13$35,13250 claims
Novo NordiskOzempic$171$35,05329 claims
Lilly USA, LLCTrulicity$109$32,08634 claims
GSKTrelegy Ellipta, Anoro Ellipta$111$25,37533 claims
AbbVieLinzess$59$11,21516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →